Biomarker Data Is the New Commercial Asset (if you can package it)

How biobanks, CROs, diagnostics labs, and research hospitals can turn existing omics data into sponsor-ready workflows, evidence packages, and revenue capacity.

“Data-rich” does not mean “commercially ready”

Biobanks, CROs, diagnostics labs, clinical genomics labs, and research hospitals are sitting on more biomarker data than ever before.

The market around this data is growing fast: one 2025 market estimate puts the global biobanking market at $81.7B in 2025, with a projected rise to $164.5B by 2034. At the same time, the AI-in-omics market is estimated at $1.21B in 2025 and projected to reach $5.14B by 2031, with pharma and biotech companies already representing the largest end-user share in 2025.

Source: Biobanking Market Size & Share 2025–2034

But the uncomfortable part is that having data and being able to commercialize it are two very different things.

Most organizations already have the raw material: FASTQ files, VCFs, RNA-seq outputs, proteomics and metabolomics tables, LIMS exports, pathology notes, clinical metadata, and years of study-specific analyses. The problem is that these assets often live in formats and systems that were never designed for repeated sponsor-facing use.

One team may know where the sequencing data is, another team may hold the clinical metadata, someone else owns the analysis scripts, and the final interpretation sits inside a PDF report from a project that ended two years ago.

Technically, the organization is data-rich. Commercially, it may still be slow to answer a simple pharma question: “Do you have the right cohort for this biomarker-driven study?”

A 2025 review in Molecular Biomedicine notes that integrating genomics, transcriptomics, proteomics, and metabolomics has enabled new applications in personalized oncology, including biomarker panels for diagnosis, prognosis, and therapeutic decision-making.

The same review is also very clear about the remaining barriers: data heterogeneity, reproducibility, and clinical validation across diverse patient populations.

So the bottleneck is data readiness.For biomarker data to become useful in pharma partnerships, it has to be discoverable, reusable, and explainable.

European personalized medicine guidance published under EP PerMed makes the same point from a research infrastructure perspective: data generated for personalized medicine should remain accessible and reusable beyond the original project, but long-term accessibility, interoperability, harmonization, and reusability are still major challenges.

Source: Guidelines for Data Reusability

Pharma buys answers that can support a decision: cohort feasibility, biomarker prevalence, responder/non-responder stratification, trial enrichment, companion diagnostic strategy, or evidence for indication expansion.

The commercial gap: pharma needs reusable answers

Biomarker data becomes commercially useful when it can answer a decision-making question more than once.

A lab may have sequencing files, RNA-seq outputs, proteomics tables, metabolomics files, LIMS exports, Excel sheets, clinical annotations, assay notes, and years of internal reports. Scientifically, that is valuable.

Commercially, it only starts to matter when the same data can be turned into repeatable answers: Do we have enough patients with this biomarker? Is this cohort feasible for a study? Can we stratify responders and non-responders? Is there enough evidence to support a biomarker hypothesis for a pharma partner?

The problem is that most internal research workflows were built around a study, a grant, a publication, a diagnostic workflow, or a one-time analysis request. Once the project ends, the data may remain stored, but the logic around it starts to decay.

The commercial value appears when these outputs can be generated repeatedly, not manually rebuilt every time a sponsor asks a new question. That is the difference between a data archive and revenue capacity.

By the way, this is exactly the workflow gap we’re building OmicsLayer™ around.

OmicsLayer™ is a AI agent for teams working with multimodal biomarker data — helping them turn fragmented datasets into reusable workflows for cohort discovery, biomarker analysis, responder/non-responder stratification, and sponsor-ready evidence packages.

Read more here: https://blackthorn.ai/omicslayer

Multi-omics makes data more valuable ( and more difficult to use)

Multi-omics has become one of the most important shifts in biomarker discovery because it gives researchers a more complete view of disease biology.

Source: Multi-omics strategies for biomarker discovery and application in personalized oncology

The value increases because the evidence becomes richer. The operational burden increases because every additional modality adds its own format, noise profile, missingness pattern, quality-control logic, normalization method, and metadata requirements.

A 2025 technical review in Briefings in Bioinformatics summarizes the problem clearly: multi-omics integration is still difficult because datasets are high-dimensional, heterogeneous, sparse, and frequently incomplete across data types.

Source: A technical review of multi-omics data integration methods

The paper also notes that multi-omics data often comes from different laboratory technologies with inconsistent distributions, and that batch correction, dimensionality reduction, and imputation are needed to make the data usable for downstream analysis.

For a scientific team, this complexity is already painful. For a commercial or partner-facing workflow, it becomes a bigger issue.

A sponsor does not want to spend weeks figuring out whether RNA-seq samples match the same patients as proteomics outputs, whether outcome labels are complete, whether assay versions changed between cohorts, whether missing values are biological or technical, or whether the final responder/non-responder analysis can be reproduced.

What “revenue capacity” actually means

It is the ability to turn that dataset into commercial outputs repeatedly, with enough structure, speed, and trust for another organization to use it in a real decision.

Market Examples of Biomarker Data Commercialization

So when we say biomarker data can become revenue capacity, we mean the organization can regularly generate outputs like:

• Sponsor feasibility packages
• Cohort discovery workflows
• Responder / non-responder analysis
• Biomarker prevalence reports
• Evidence packages for pharma partners
• Reusable data products

The business model depends on the organization.

A diagnostics company may monetize through clinical testing first, then create biopharma data and development services on top. A real-world-data company may monetize curated datasets, evidence-generation workflows, and subscription or project-based access. A bioinformatics platform may monetize analytics software, trial-matching workflows, data reports, and partner applications. A CRO or lab may monetize faster sponsor feasibility, sample intelligence, LIMS/ELN-linked reports, and repeatable evidence packages.

That is revenue capacity. It is the operational ability to turn existing biomarker data into repeatable, trusted, decision-ready outputs.

And once that layer exists, the commercial model becomes much more flexible. The organization can sell feasibility work packages, evidence reports, trial-enrichment support, cohort discovery, pharma partner analytics, CDx-supporting workflows, or data products built around specific indications and biomarkers.

We put together a short Biomarker data commercial readiness questionnaire (with input from the scientific, data, and legal/compliance side). 35 questions to help teams check how ready their biomarker / omics / clinical data is for reuse, sponsor workflows, and commercial packaging.

Try it and let us know if it was useful!

Conclusions

So, biomarker data is becoming a real commercial asset, but only when it can be packaged into something pharma can actually use.

“Revenue capacity” means operational repeatability. It is the ability to turn existing biomarker data into commercial outputs again and again: sponsor feasibility packages, cohort discovery workflows, responder analysis, prevalence reports, evidence packages, and reusable data products.

Once this layer exists, the same structured dataset can support multiple sponsors, studies, indications, and partnership conversations.

Want to turn your biomarker data into a commercial asset?

This is exactly why we built OmicsLayer™ — an AI agent for teams working with multimodal biomarker data, cohort metadata, clinical annotations, and sponsor-facing evidence workflows.

With OmicsLayer™, teams can:

• Generate +EUR 150k–500k/year in additional pharma-partner revenue by packaging biomarker analysis, cohort selection, trial feasibility evidence, and responder/non-responder stratification into higher-value sponsor work packages.
• Improve cohort-screening efficiency by 10–25% by standardizing how cohorts, biomarkers, and supporting evidence are prepared for sponsor review.
• Protect EUR 40k–120k/year in project margin by reducing repeated manual preparation across data science, bioinformatics, and modality teams.
• Answer sponsor feasibility questions 40–70% faster by using searchable cohorts, biomarkers, files, analysis outputs, and provenance instead of rebuilding every request manually.

Explore OmicsLayer™